Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Trial ID or NCT#
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
- - Male and Female Patients at least 18 years old - Patient who have rare tumors of neuroendocrine origin, such as tumors of the: 1. pancreas 2. pituitary glands 3. Nelson syndrome 4. ectopic-ACTH secreting tumor - Patients who have failed standard of care treatment or for whom no standard of care treatment exist - Signed Informed Consent
- - Patients with active gallbladder disease - Patients with any ongoing or planned anti-neoplastic or interferon therapy - Poorly controlled diabetes mellitus - Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control Other protocol-defined inclusion/exclusion criteria may apply.
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
About this Clinical Trial
Your Message Will Go ToCancer Clinical Trials Office
To:Cancer Clinical Trials Office
Go Back To The Trial